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Here, we describe a nonsense haplotype in PRNP associated with clinical Alzheimer’s disease. The patient
presented an early-onset of cognitive decline with memory loss as the primary cognitive problem.
Whole-exome sequencing revealed a nonsense mutation in PRNP (NM_000311, c.C478T; p.Q160*;
rs80356711) associated with homozygosity for the V allele at position 129 of the protein, further high-
lighting how very similar genotypes in PRNP result in strikingly different phenotypes.
 2014 The Authors. Published by Elsevier Inc. All rights reserved.1. Introduction
Alzheimer’s disease (AD) is a complex disorder with some cases
known to be caused bymutations in 3 genes: the amyloid precursor
protein (APP), Presenilin 1 (PSEN1), and Presenilin 2 (PSEN2). The
Apolipoprotein E E4 allele increases the risk of AD by 3- to 15-fold,
although several genetic loci (CLU, PICALM, CR1, BIN1,MS4A, CD2AP,
CD33, EPHA1, ABCA7, CD2AP, HLA-DRB5/DRB1, SORL1, PTK2B,
SLC24A4, ZCWPW1, CELF1, FERMT2, CASS4, INPP5D, MEF2C, NME8)
have a low effect on disease risk (Guerreiro et al., 2013a). More
recently, the application of exome sequencing to large cohorts of AD
cases and healthy controls led to the identiﬁcation of rare hetero-
zygous variants in TREM2 and PLD3 as medium effect risk factors for
the disease (Cruchaga et al., 2013; Guerreiro et al., 2013b; Jonsson
et al., 2013).
The application of this technology to the study of small families
and individual cases with different forms of dementia has also
resulted in the association of unexpected molecular causes toe CC BY license (http://
r Neuroscience, UCL Institute
are, London WC1N 3BG, UK.
7.
Published by Elsevier Inc. All righdifferent clinical phenotypes (for a review see, Guerreiro et al.,
2014). For example, TREM2 homozygous mutations, known to be
the cause of Nasu-Hakola disease, were recently found to also cause
frontotemporal dementia with no associated bone phenotypes
(Guerreiro et al., 2013c); homozygous mutations in ATP13A2 (a gene
known to cause Kufor-Rakeb) and GRN (where heterozygous mu-
tations cause frontotemporal dementia) were identiﬁed in families
with neuronal ceroid-lipofuscinosis (Bras et al., 2012a; Smith et al.,
2012). Exome sequencing has not only allowed the identiﬁcation of
the genetic causes of disease in cases that otherwise would have
never been screened for mutations in the implicated genes because
of their atypical phenotypes, but has also uncovered common
biological pathways between different clinical entities (Bras et al.,
2012b).
Here, we describe one more of these cases: a patient clinically
diagnosed with AD found by exome sequencing to harbor a
nonsense mutation in the PRNP gene.
2. Methods
When genetic tests for APP, PSEN1, and PSEN2 revealed
no mutations, the patient was included in a whole-exome
sequencing study. Genomic DNA was prepared according to
Illumina’s TruSeq Sample Preparation v3 (Illumina, CA, USA)
and capture was performed with Illumina’s TruSeq Exomets reserved.
Table 1
Main characteristics of cases reported in the literature with PRNP nonsense mutations
Mutation M129V
poly
Gender Origin AAO (y) AAD (y) Clinical features Pathology features Presence
of
diarrhea
Family history Reference
Y145* (rs80356710) F Japanese 38 59 Alzheimer type clinical course Many amyloid plaques (PrP) and
diffuse neuropil threads of paired
helical ﬁlaments
Kitamoto
et al. (1993)
Y145* (rs80356710) probably
the same case described by
Kitamoto et al.
M/M Japanese 38 59 Slowly progressive dementia Severe diffuse atrophy of the
cerebrum and dilation of the lateral
ventricles; amyloid deposits in
parenchymal and leptomeningeal
blood vessels and in the perivascular
neuropil; neuroﬁbrillary lesions
“Family
history is not
contributory”
Ghetti et al.
(1996)
Q160* (rs80356711) Proband:
M/M
Brother:
M/V
(mutation
on the M
allele)
M Austrian Proband: 32
Brother: 48
Slowly progressive dementia No postmortem Not noted Brother and
father also
with dementia
onset at 48 y
and reported
to have died at
60 y
Finckh et al.
(2000)
Q160* (rs80356711) Proband:
M/V
Mother:
M/M
F Proband: 39
Mother: 59
47 The clinical and initial
pathologic features in both
patients were strongly
suggestive of AD
Proband: abundant limbic and
neocortical neuritic plaque-like
structures and NFTs, consistent with
a neuropathologic diagnosis of AD.
Immunohistochemical studies: PrP
immunopositive deposits.
Mother: severe neuroﬁbrillary
tangles and neuritic plaque
pathology in frontal cortex and
hippocampus. Classic Lewy bodies
and alpha-synuclein
immunopositive inclusions and
neurites.
Nothing
noted in
the
proband
but
present in
the
mother
Mother with
the same
disease
Jayadev
et al. (2011)
Y163* Mutation
in the V
allele
Fourth decade
with cognitive
problems and
seizures
starting on the
ﬁfth and sixth
decade
Average
of 57
(range 40
e70)
Chronic diarrhea with
autonomic failure and a length-
dependent axonal,
predominantly sensory,
peripheral polyneuropathy.
PrP-amyloid deposition was seen
throughout the peripheral organs,
including the bowel and peripheral
nerves. Neuropathologic
examination at end stage
demonstrated PrP deposition in the
form of frequent cortical amyloid
plaques, cerebral amyloid
angiopathy, and tauopathy. A unique
pattern of abnormal PrP fragments
was seen in brain tissue.
Yes Dominant
trait
Mead et al.
(2013)
Y163* probably the same
family reported by Mead S,
et al.
Clinical diagnosis of hereditary
sensory and autonomic
neuropathy: chronic diarrhea,
profound autonomic failure,
and predominantly axonal
sensory peripheral neuropathy
in early adulthood.
Extensive central nervous system
prion protein deposition including
cerebral amyloid angiopathy and
secondary tauopathy. Abnormal
prion protein deposition was also
seen in the duodenum.
Yes 9 patients
from 1 family
http://dx.
doi.org/10.
1136/jnnp.
2010.
226340.31
Y163* probably the same case
as reported in previous
entrance and by Mead, S
et al.
PrPSc deposition in blood vessels
and parenchyma.
Revesz
et al. (2009)
(continued on next page)
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Sequencing was performed in Illumina’s HiSeq2000 using 100 bp
paired-end reads. Sequence alignment and variant calling were
performed against the reference human genome (UCSC hg19)
using bwa (Li and Durbin, 2009) and reads processed according
with the Genome Analysis Toolkit best practices (McKenna et al.,
2010). Variants were called using UniﬁedGenotyper and recali-
brated using VQSR, both tools from the GATK. Finally, variants
were annotated using snpEff (Cingolani et al., 2012). The PRNP
mutation was conﬁrmed by Sanger sequencing using standard
methodology.
3. Results
The analysis of the exome sequencing data conﬁrmed the
absence of pathogenic mutations in APP, PSEN1, and PSEN2. Addi-
tionally, no coding variants were found in the dementia associated
genes APP, PSEN2, GRN, TREM2, or PLD3. The patient was found to
carry the PSEN1 (NM_000021) p.E318G and the MAPT
(NM_001123066) p.Q230R variants.
Further inspection of the 9423 coding variants found (445 of
which were novel), revealed a nonsense mutation in PRNP
(NM_000311, c.C478T; p.Q160*; rs80356711) associated with ho-
mozygosity for the V allele at position 129 of the protein.
The patient was followed in the Mayo Clinic and presented an
early-onset of cognitive decline at 38 years withmemory loss as the
primary cognitive problem, but also showing an impulsive behavior
on her neuropsychological assessment. Her mother had a similar
problem, also of early onset (no DNA was available for testing). Her
maternal grandparents lived long and were said not to be affected.
Her brother and daughter were also unaffected at the time of
evaluation. She had temporary diarrhea, which was thought to be
related to the introduction of Aricept, and her positron emission
tomography scan showed left frontal hypometabolism. The patient
was diagnosed with clinical AD and no neuropathologic assessment
was possible.
4. Discussion
The mutation here described (p.Q160*) has been previously re-
ported in 2 other cases (Table 1) diagnosed with an Alzheimer-like
dementia. The ﬁrst case did not have a detailed clinical description
and no pathologic ﬁndings were reported (Finckh et al., 2000). The
second case was deeply phenotyped, and neuropathologic evalua-
tion showed abundant limbic and neocortical neuritic plaque-like
structures and neuroﬁbrillary tangles consistent with a neuro-
pathologic diagnosis of AD. Immunohistochemical studies also
demonstrated PrP immunopositive deposits (Jayadev et al., 2011).
In the literature, 6 different mutations in PRNP leading to a
premature truncation of the protein can be found (Table 1). None of
these cases was initially diagnosed with a prion disease. In fact, the
proband’s mother in the report by Jayadev et al. (2011) was also
neuropathologically diagnosed as AD before immunochemical
studies were performed.
Recently, Mead et al. (2013) described an unusual phenotype
associated with a novel nonsense mutation in PRNP. The affected
members of this family carried the p.129V-163* PRNP truncation
haplotype and developed autonomic failure with chronic diarrhea
and peripheral polyneuropathy in adulthood.
The different truncating mutations in PRNP appear to have some
common features namely: prolonged clinical courses, atypical for
prion diseases, severe neuroﬁbrillary tangle pathology, and high
levels of cerebral amyloidosis. However, it is remarkable that the
simple removal of an extra 3 amino acids on the same haplotype
(V129 background), consistently results in a very different
R. Guerreiro et al. / Neurobiology of Aging 35 (2014) 2656.e13e2656.e162656.e16phenotype: truncated PRNP at amino acids 160 or 163 present with
a clear hippocampal involvement or an autonomic defect,
respectively.
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